PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE BREAST CANCER AS A POTENTIAL TARGET FOR FUTURE DRUG DISCOVERY
Breast cancer is the most common malignancy in women globally, in which triple-negative breast cancer (TNBC) is more aggressive with poor prognosis and very less response to targeted hormone based treatment. It is a major cause of deaths among the women with breast cancer because of very few treatment options. The biomarkers could be a product of cancerous cell or molecule generated in response to cancer. It is used to understand the mechanism, prognosis, diagnosis as well as target for design and discovery of new drugs. The purpose of the study is to give a brief review on
markers of TNBC.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492-502.
3. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: Review. Pathology 2009;41(1):40-7.
4. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26(26):4282-8.
5. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17(5):1082-9.
6. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008;22(11):1233-9.
7. Prat A, Pineda E, Adamo B, GalvÃ¡n P, FernÃ¡ndez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24 Suppl 2:S26-35.
8. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
9. SÃ¸rlie T, Perou CM, Tibshirani R, Aasf T, Geislerg S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguishes tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98(19):10869-74.
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100(14):8418-23.
11. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015;6(15):12890-908.
12. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121(7):2750-67.
13. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-85.
14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: Decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011;12(2):104-17.
15. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: Not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol2014;6(4):a020768.
16. Arteaga CL, Engelman JA. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25(3):282-303.
17. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984;311(5985):483-5.
18. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309(5967):418-25.
19. Quintela I, Corte MD, Allende MT, Vazquez J, RodrÃguez JC, Bongera M, et al. Expression and prognostic value of EGFR in invasive breast cancer. Oncol Rep 2005;14(6):1655-63.
20. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem 2015;84:739-64.
21. Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma. Beijing Da Xue Xue Bao 2012;44(5):666-72.
22. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009;118(1):131-7.
23. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the triple-negativeâ€ phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009;116(2):317-28.
24. Oliveras-Ferraros C, Vazquez-Martin A, LÃ³pez-Bonet E, MartÃn-Castillo B, Del Barco S, Brunet J, et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol 2008;33(6):1165-76.
25. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012;136(2):331-45.
26. Carey LA. Neoadjuvant trials of human epidermal growth factor receptor 2 targeting: How many drugs do we need? J Clin Oncol 2012;30(16):1909-11.
27. Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, Rakheja D, et al. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol 2010;134(5):782-7.
28. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991;12(1):42-9.
29. Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol 2011;67(4):911-7.
30. Zheng JN, Sun YF, Pei DS, Liu JJ, Ma TX, Han RF, et al. Treatment with vector-expressed small hairpin RNAs against Ki67 RNA-induced cell growth inhibition and apoptosis in human renal carcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2006;38(4):254-61.
31. Li H, Han X, Liu Y, Liu G, Dong G. Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. Oncol Lett 2015;9(1):149-52.
32. Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol 2011;135(2):230-7.
33. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011;13(2):R22.
34. Jones RL, Salter J, Aâ€™Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116(1):53-68.
35. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Aâ€™Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99(2):167-70.
36. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: Usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 2011;13(6):R122.
37. Viale G. Pathological work up of the primary tumor: Getting the proper information out of it. Breast 2011;20 Suppl 3:S82-6.
38. Kos Z, Dabbs DJ. Biomarker assessment and molecular testing for prognostication in breast cancer. Histopathology 2016;68(1):70-85.
39. Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast 2015;24 Suppl 2:S67-72.
40. Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: Focus on angiogenesis. J Oncol 2012;2012:281261.
41. Grimm D, Bauer J, Ulbrich C, Westphal K, Wehland M, Infanger M, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity. Tissue Eng Part A 2010;16(5):1559-73.
42. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013;273(2):114-27.
43. Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14(5):9338-64.
44. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: More than one way to skin a cat - Implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32(2):71-87.
45. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9.
46. Mackey J, Gelmon K, Martin M, McCarthy N, Pinter T, Rupin M, et al. TRIO-012: A multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer 2009;9(4):258-61.
47. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997;94(16):8761-6.
48. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 19982;273(21):13313-6.
49. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - In control of vascular function. Nat Rev Mol Cell Biol 2006;7(5):359-71.
50. El-Arab LR, Swellam M, El Mahdy MM. Metronomic chemotherapy in metastatic breast cancer: Impact on VEGF. J Egypt Natl Canc Inst 2012;24(1):15-22.
51. Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H, et al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem 2009;42(13-14):1420-6.
52. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6(10):3923-31.
53. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008;17(4):301-11.
54. Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, et al. Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. Exp Ther Med 2011;2(2):257-64.
55. Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 2010;17(5):1398-405.
56. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6(1):R24-30.
57. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004;198(1):83-90.
58. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102(38):13550-5. 59. Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol 2011;41(2):172-9.
60. Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39(4):217-24.
61. Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol 2016;49(1):11-21.
62. Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. J Breast Cancer 2015;18(1):16-21.
63. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, EspiÃ© M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 2013;132(5):1227-31.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.